Today, August 05, 2021, a meeting of the Commission of the Ministry of Health of the Russian Federation on the formation of lists of drugs for human use and the minimum range of drugs required for the provision of medical care was held. During the meeting, the Commission decided to include Orkambi—a drug for the treatment of cystic fibrosis in patients aged 6 years and older and homozygous for the F508del mutation in the CFTR gene—in the List of Vital and Essential Drugs (VED). The cost of the drug will now be fixed.
In a few days, the minutes of the meeting will be posted on the website of the Ministry of Health of the Russian Federation. The corresponding Government decree will be issued this November.